Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan

被引：0
作者：
Takashi Ogura
Yoshikazu Inoue
Arata Azuma
Sakae Homma
Yasuhiro Kondoh
Katsumi Tanaka
Kaori Ochiai
Yukihiko Sugiyama
Toshihiro Nukiwa
机构：
[1] Kanagawa Cardiovascular and Respiratory Center,Department of Respiratory Medicine
[2] National Hospital Organization Kinki-Chuo Chest Medical Center,Clinical Research Center
[3] Nippon Medical School Graduate School of Medicine,Department of Respiratory Medicine, School of Medicine
[4] Toho University,Department of Respiratory Medicine and Allergy
[5] Tosei General Hospital,Patient Safety and Pharmacovigilance Department
[6] Nippon Boehringer Ingelheim Co.,Division of Pulmonary Medicine, Department of Medicine
[7] Ltd.,Department of Respiratory Medicine
[8] PMS Center,undefined
[9] EPS Corporation,undefined
[10] Nerima Hikarigaoka Hospital,undefined
[11] Tohoku University,undefined
来源：
Advances in Therapy | 2023年 / 40卷 / 4期
关键词：
Adverse drug reactions; Idiopathic pulmonary fibrosis; Nintedanib; Post-marketing surveillance study; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1474 / 1493
页数：19
相关论文
共 88 条
[1]  
Kondoh Y(2022)Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis Respir Res 23 24-779
[2]  
Suda T(2014)Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences Am J Respir Crit Care Med 190 773-291
[3]  
Hongo Y(2018)Japanese guideline for the treatment of idiopathic pulmonary fibrosis Respir Investig 56 268-2082
[4]  
Natsuizaka M(2014)Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N Engl J Med 370 2071-79
[5]  
Chiba H(2016)Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials Respir Med 113 74-68
[6]  
Kuronuma K(2019)Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON Lancet Respir Med 7 60-757
[7]  
Homma S(2017)Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: a subgroup analysis of the INPULSIS® randomized trials Respirology 22 750-21
[8]  
Bando M(2018)Understanding and misunderstanding randomized controlled trials Soc Sci Med 210 2-106
[9]  
Azuma A(2016)Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis Respiration 92 98-1178
[10]  
Richeldi L(2017)Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions Respirology 22 1171-66
123456789